BioSpace - Argos Therapeutics, Inc. News, Search Jobs, Events

Industry

Collaborations

Duke University Exclusive license to the RNA based vaccine technology.

Rockefeller University Exclusive worldwide rights to technology developed at Rockefeller relating to generation of dendritic cells.

Baylor University Clinical and preclinical research in Lupus.

Kirin Brewery Co., Ltd. The companies will collaborate to develop and commercialize dendritic cell vaccines, initially in the areas of cancer and infectious diseases.

Erlangen University Clinical and preclinical research in Melanoma.

Argos Therapeutics, Inc. to Present at the Sachs Cancer Bio Partnering Forum 5/20/2013 9:43:33 AM More...

Argos Therapeutics, Inc. Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response 5/8/2013 1:53:19 PM More...

Argos Therapeutics, Inc. to Present at the 12th Annual Needham Healthcare Conference 4/30/2013 2:27:21 PM More...

Argos Therapeutics, Inc. Welcomes Jean Lamarre to Board of Directors 3/13/2013 12:27:23 PM More...

Argos Therapeutics, Inc. Validates Durability of AGS-003 Induced Immune Response in mRCC Patients 3/4/2013 11:28:51 AM More...

Argos Therapeutics, Inc. Announces Updated Phase 2 Data for AGS-003 Personalized Immunotherapy for Metastatic Renal Cell Carcinoma 2/15/2013 9:42:11 AM More...

Argos Therapeutics, Inc. to Present on Automated Manufacturing Process at 2013 Cell and Gene Therapy Forum 1/28/2013 9:04:29 AM More...

Argos Therapeutics, Inc. Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study 1/15/2013 10:03:00 AM More...

Argos Therapeutics, Inc. Study Confirms Optimal Quality Control Methods for Production of Its RNA-Based Immunotherapies 11/16/2012 7:16:01 AM More...

Southeast BIO (SEBIO) Recognizes Argos Therapeutics, Inc. With the "2012 Southeast BIO Deal of the Year: Venture Capital Transaction" Award 11/2/2012 7:16:09 AM More...

...